SCHEMBL1298623

SCHEMBL1298623

O=c1nccc2[nH]cncc1-2

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 13/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2E1 P05181 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ASIC3 Q9UHC3 1/20 0.36
HPGDS O60760 1/20 0.36
CYP1A2 P05177 1/20 0.36
TDO2 P48775 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7854 0.71
SCHEMBL3141716 0.71 IDO1 (0.44) IDO1CYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL3474476 0.71 AURKA (0.45) POLB
Ammonia Solution, Strong SCHEMBL27003885 0.69 CYP3A4 (0.42) IDO1CYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL20772034 0.69 CYP3A4 (0.42) IDO1CYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL10506714 0.69 KDM4A (0.33) IDO1CYP3A4CYP2D6CYP2E1CYP2A6
Hydrochloric Acid SCHEMBL11257477 0.69 IDO1 (0.43) IDO1CYP3A4CYP2D6CYP2E1CYP2A6
Hydrochloric Acid SCHEMBL30685515 0.68 AURKA (0.42) POLB
Bicarbonate SCHEMBL28123369 0.68 KDM4C (0.41) IDO1CYP3A4CYP2D6CYP2E1CYP2A6
Phosphoric Acid SCHEMBL1880808 0.67 IDO1 (0.37) IDO1CYP3A4CYP2D6CYP2E1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370103-A2 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO[4,3-D]PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR Novartis AG (CH) 2011-10-05 EP claimed
WO-2010060939-A2 COMBINATION OF HSP90 AND HERCEPTIN INHIBITORS NOVARTIS AG (CH) 2010-06-03 WO claimed
EP-4516359-A3 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY Oncoceutics, Inc. (US) 2025-04-23 EP disclosed
EP-4512483-A3 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY Oncoceutics, Inc. (US) 2025-04-23 EP disclosed
EP-4516359-A2 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY Oncoceutics, Inc. (US) 2025-03-05 EP disclosed
EP-4512483-A2 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY Oncoceutics, Inc. (US) 2025-02-26 EP disclosed
US-20240254123-A1 PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS APREA THERAPEUTICS, INC. 2024-08-01 US disclosed
EP-4347592-A1 PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS Aprea Therapeutics, Inc. (US) 2024-04-10 EP disclosed
EP-3728217-B1 CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL INC (US) 2023-11-15 EP disclosed
WO-2022256680-A1 PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS ATRIN PHARMACEUTICALS (US) 2022-12-08 WO disclosed
WO-2018011570-A1 WEE-1 INHIBITING PYRIDOPYRIMIDINONE COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2018-01-18 WO disclosed
WO-2011053861-A8 KINASE INHIBITORS GENOSCO (US) 2011-10-27 WO disclosed
WO-2011053861-A1 KINASE INHIBITORS GENOSCO (US) 2011-05-05 WO disclosed
EP-1928875-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDOÝ4,3-D¨PYRIMIDIN-5-ONES Novartis AG (CH) 2008-06-11 EP disclosed
WO-2007041362-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES NOVARTIS AG (CH) 2007-04-12 WO disclosed
US-4681881-A 5-alkoxy-pyrido[4,3-d]pyrimidine derivatives GODECKE AKTIENGESELLSCHAFT (DE) 1987-07-21 US disclosed
US-4681885-A 5-oxo-pyrido[4,3-]pyrimidine derivatives GODECKE AKTIENGESELLSCHAFT (DE) 1987-07-21 US disclosed
US-4681885-A 5-oxo-pyrido[4,3-]pyrimidine derivatives GODECKE AKTIENGESELLSCHAFT (DE) 1987-07-21 US disclosed
EP-0189870-A1 5-Alkoxy-pyrido[4,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them GÖDECKE AKTIENGESELLSCHAFT (DE) 1986-08-06 EP disclosed
EP-0189883-A1 5-Oxo-pyrido[4,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them GÖDECKE AKTIENGESELLSCHAFT (DE) 1986-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254123-A1 PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS WEE1, WEE2, NME1 IDO1 3228/4885CYP3A4 2845/4885CYP2D6 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.